rs730880116
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000238.4(KCNH2):c.685G>T(p.Glu229Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. E229E) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000238.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
KCNH2 | NM_000238.4 | c.685G>T | p.Glu229Ter | stop_gained | 4/15 | ENST00000262186.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
KCNH2 | ENST00000262186.10 | c.685G>T | p.Glu229Ter | stop_gained | 4/15 | 1 | NM_000238.4 | P1 | |
KCNH2 | ENST00000532957.5 | n.908G>T | non_coding_transcript_exon_variant | 4/9 | 2 | ||||
KCNH2 | ENST00000684241.1 | n.1518G>T | non_coding_transcript_exon_variant | 2/13 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1314242Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 648660
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Long QT syndrome 2 Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Blueprint Genetics | Oct 07, 2014 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 09, 2016 | The E229X pathogenic variant in the KCNH2 gene has been previously reported in multiple individuals in association with LQTS (Tester et al., 2005; Tester et al., 2006; Berge et al., 2008; Goldenberg et al., 2011). This variant was also observed in one affected individual from a family referred for LQTS genetic testing at GeneDx, and was found to segregate with a prolonged QT interval in a second family member. E229X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Furthermore, multiple other nonsense variants in the KCNH2 gene have been reported in the Human Gene Mutation Database in association with LQTS (Stenson et al., 2014). Finally, while data from control individuals was not sufficient to assess whether E229X may be a common benign variant in the general population, Tester et al. (2005) previously reported E229X to be absent from over 1,400 reference alleles.In summary, E229X in the KCNH2 gene is interpreted as a pathogenic variant. - |
Long QT syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 26, 2023 | This sequence change creates a premature translational stop signal (p.Glu229*) in the KCNH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in KCNH2 are known to be pathogenic (PMID: 10973849, 19862833). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with undergoing testing for long QT syndrome (PMID: 15840476, 16818214, 18752142, 19716085). ClinVar contains an entry for this variant (Variation ID: 180379). For these reasons, this variant has been classified as Pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 01, 2018 | The p.E229* pathogenic mutation (also known as c.685G>T), located in coding exon 4 of the KCNH2 gene, results from a G to T substitution at nucleotide position 685. This changes the amino acid from a glutamic acid to a stop codon within coding exon 4. This mutation has been reported in multiple unrelated probands in several publications on long QT syndrome clinical genetic testing; however, clinical details are limited (Kapplinger JD et al. Heart Rhythm, 2009 Sep;6:1297-303; Tester DJ et al. Heart Rhythm, 2005 May;2:507-17; Berge KE et al. Scand. J. Clin. Lab. Invest., 2008;68:362-8; Tester DJ et al. Heart Rhythm, 2006 Jul;3:815-21). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at